To study the effect of post-transplant cyclophosphamide pharmacology with transplant outcomes in patients undergoing haploidentical hematopoietic stem cell transplantatio
Not Applicable
Completed
- Conditions
- Health Condition 1: null- Patients of acute leukemia
- Registration Number
- CTRI/2018/08/015152
- Lead Sponsor
- Department of Internal Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 30
Inclusion Criteria
1. Patients receiving either myeloablative or reduced intensity conditioning.
2. Patients receiving post-transplant cyclophosphamide as a part of haploidentical transplantation.
3. Patients consenting for study.
Exclusion Criteria
1. Patients not willing for haploidentical hematopoietic cell transplantation
2. Patients who are unable to follow up for one year.
3. Patients not a candidate for haploidentical HCT or as deemed unfit for HCT by treating
physician as per established unit protocol
4. Patients other than acute leukemia undergoing haploidentical HCT
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival <br/ ><br>Regimen related toxicity <br/ ><br>Graft versus Host disease <br/ ><br>Overall survival <br/ ><br>Timepoint: 100 days after transplant, <br/ ><br>1 year post transplant <br/ ><br>
- Secondary Outcome Measures
Name Time Method Immune Reconstitution will be assessed.Timepoint: At 4th, 12th,24th and 51 week after transplant.